key: cord-0905632-lsqz5qt3 authors: Peng, Yudong; Meng, Kai; He, Meian; Zhu, Ruirui; Guan, Hongquan; Ke, Zihan; Leng, Liang; Wang, Xiang; Liu, Bende; Hu, Caiying; Ji, Qingwei; Keerman, Mulatibieke; Cheng, Longxian; Wu, Tangchun; Huang, Kai; Zeng, Qiutang title: Clinical Characteristics and Prognosis of 244 Cardiovascular Patients Suffering From Coronavirus Disease in Wuhan, China date: 2020-09-22 journal: J Am Heart Assoc DOI: 10.1161/jaha.120.016796 sha: 94fd59ce7f8dfb7576bf4ba1d3bb112f87cd00a0 doc_id: 905632 cord_uid: lsqz5qt3 BACKGROUND: The coronavirus disease 2019 (COVID‐19) has developed into a global outbreak. Patients with cardiovascular disease (CVD) with COVID‐19 have different clinical characteristics and prognostic outcomes. This study aimed to summarize the clinical characteristics and laboratory indicators of patients with COVID‐19 with CVD, especially the critically ill patients. METHODS AND RESULTS: This study included 244 patients diagnosed with COVID‐19 and CVD (hypertension, coronary heart disease, or heart failure). The patients were categorized into critical (n=36) and noncritical (n=208) groups according to the interim guidance of China’s National Health Commission. Clinical, laboratory, and outcome data were collected from the patients’ medical records and compared between the 2 groups. The average body mass index of patients was significantly higher in the critical group than in the noncritical group. Neutrophil/lymphocyte ratio, and C‐reactive protein, procalcitonin, and fibrinogen, and d‐dimer levels at admission were significantly increased in the critical group. The all‐cause mortality rate among cases of COVID‐19 combined with CVD was 19.26%; the proportion of coronary heart disease and heart failure was significantly higher in deceased patients than in recovered patients. High body mass index, previous history of coronary heart disease, lactic acid accumulation, and a decrease in the partial pressure of oxygen were associated with death. CONCLUSIONS: All‐cause mortality in patients with COVID‐19 with CVD in hospitals is high. The high neutrophil/lymphocyte ratio may be a predictor of critical patients. Overweight/obesity combined with coronary heart disease, severe hypoxia, and lactic acid accumulation resulting from respiratory failure are related to poor outcomes. REGISTRATION: URL: https://www.chictr.org.cn; Unique identifier: ChiCTR2000029865. The data that support the findings of this study are available from the corresponding author upon reasonable request. All data and materials have been made publicly available at the Chinese Clinical Trial Registry and can be accessed at http://www.chictr. org.cn. We recruited patients from January 10 to February 25, 2020, receiving medical intervention who were cured or who died (clinical end point) at the West District of Union Hospital, Union Wuhan Red Cross Hospital, and Union Jiangnan Hospital in Wuhan, China. This study was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology, and was registered in the Chinese Clinical Trial Registry (No. ChiCTR2000029865). Written informed consent was obtained from the patients involved or next of kin before enrollment. Adult patients (aged >18 years) were admitted to the 3 hospitals in Wuhan city. In total, 850 patients diagnosed with COVID-19 according to the interim guidance of China's National Health Commission were screened for inclusion in this study 9 ; of these, 278 patients also had CVD. CVD included previous diagnoses of hypertension, coronary heart disease (CHD), and heart failure (HF). The diagnosis and treatment of hypertension and HF were based on the corresponding guidelines. 10, 11 CHD was diagnosed by coronary angiography or coronary computed tomography (CT) showing at least 1 epicardial main vessel stenosis of >50% in diameter or a clear history of old myocardial infarction. After excluding patients with systemic diseases or severe liver or kidney dysfunction, 244 patients were enrolled for further analysis. All diagnoses and treatments were conducted in strict accordance with the interim guidance of the National Health Commission. 9 Patients were categorized into the critical and noncritical groups according to the disease severity. Briefly, those with any of the following conditions were classified as critical (n=36): respiratory failure requiring mechanical ventilation, shock, and combined organ failure requiring intensive care unit monitoring and treatment. 9 In the noncritical group (n=208), patients with fever, respiratory symptoms, pneumonia confirmed by imaging, and other features were classified as having a mild disease. Those with any of the following conditions were classified as having a severe disease: respiratory distress with a respiratory rate of ≥30 beats/min; at rest, finger oxygen What Is New? • The study comprehensively describes the phenotypic and biochemical characteristics of those with a previous history of cardiovascular disease and were admitted with coronavirus disease 2019. • We found that neutrophil/lymphocyte ratio, C-reactive protein, procalcitonin, fibrinogen, and d-dimer levels at admission were significantly increased in those who develop critical disease; and those with higher body mass index, lactate levels, or previous history of coronary heart disease were more likely to die as compared with those who did not. What Are the Clinical Implications? • There are distinct phenotypic and laboratory patterns that are associated with increase in mortality among those with previous cardiovascular disease and admitted with coronavirus disease 2019. • It is important to identify these patients early to improve their outcomes. A patient was considered cured if there was a significant improvement in or disappearance of clinical symptoms and a significant improvement in lung CT images, and the patient showed negative nucleic acid tests for SARS-CoV-2 on 2 different days (simultaneously available). 9 Death was defined as all-cause death in the hospital. We collected the clinical, laboratory, and outcome data from the patients' medical records. The clinical outcomes were observed until February 25, 2020. Two researchers independently reviewed the medical records and collected the data. Values are presented as mean±SE, median (interquartile range [IQR]), or percentage in each group. Statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC). Differences were evaluated using 1-way ANOVA and the Newman-Keuls method. The means continuous variables were compared using independent group t-tests when the data were normally distributed; otherwise, the Mann-Whitney U test was used. Proportions for categorical variables were compared using the chi-squared test. A P value of <0.05 was considered statistically significant. A multivariate logistic regression model was applied to analyze factors potentially related to the disease outcome. Basic patient information upon admission is shown in Characteristic chest CT images are shown in the Figure The differences in the laboratory parameters, including blood cell count and C-reactive protein, procalcitonin, CK, CK-MB, troponin I, AST, LDH, fibrinogen, and d-dimer levels, between the 2 groups are shown in Table 2 . The white blood cell count of most patients was normal at admission, with no significant difference between the critical and noncritical groups ( We further analyzed the potential factors related to the clinical prognosis ( To investigate the potential factors related to the clinical outcome, we conducted further logistical regression. Baseline variables that were considered clinically relevant or that showed a univariate relationship with the outcome were introduced into the multivariate logistic regression model. 13 Considering the relatively small sample size in the present study, the results should be interpreted carefully. As shown in Table 4 , patients who We also performed propensity-adjusted analysis to balance the baseline demographics between the 2 groups, and the results did not change (data not shown). From January 10, 2020, to February 25, 2020, 850 patients with COVID-19 were screened. The percentage of patients with COVID-19 and CVD (32.70%; 278/850) was consistent with that reported previously, 7,8 without significant difference between sexes. The prognosis of COVID-19 combined with CVD was significantly poorer than that of COVID-19 alone. 8, 14 Our results indicated that critical patients with both COVID-19 and CVD had a significantly higher mortality risk than noncritical patients. In addition, patients with CVD who were overweight/obese tended to have a poor prognosis, which may be attributable to excessive inflammatory responses 8 and hypoxia, as well as inflammatory factors associated with snoring. 15, 16 Hypertension, the most common complication among the 3 observed types of CVD, proved to be related to mild illness in these cases. Patients with CHD or HF tended to have more severe illness and had worse clinical outcomes. We observed that the shorter the time from onset to admission, the lower the severity of the disease and the better the prognosis. This, however, is merely because of the different prognoses, and not a predictor of prognosis. Respiratory failure was the leading cause of death, followed by AMI and HF. In addition, cerebrovascular accidents cannot be ignored. The laboratory index of patients with COVID-19 with CVD revealed certain characteristics. The white blood cell counts of most patients were normal at admission, and leukocyte and neutrophil counts were increased when patients with severe diseases had bacterial infections. However, because SARS-CoV-2 consumed a large number of CD4 + and CD8 + T lymphocytes, 8, 17 the lymphocyte count was generally decreased, and the neutrophil/lymphocyte ratio may be used as an intuitive indicator of clinical severity. A recent study showed that the eosinophil count was also significantly decreased. 18 SARS-CoV-2 infection did not directly affect liver and kidney functions, lipid profile, or activated partial thromboplastin time in patients with CVD, but the fibrinogen and d-dimer levels were significantly increased at admission in critical patients. This might be associated with vomiting and a poor appetite, reduced blood volume, and the need for invasive procedures, such as vascular puncture; extensive inflammatory damage to the vascular endothelium also activated the clotting system. 19 Recent research has confirmed that cardiac injury is common among hospitalized patients with COVID-19 associated with a higher risk of in-hospital mortality. However, in these early studies, observational indicators were limited to high-sensitivity troponin or CK-MB. 20, 21 Troponin and CK-MB had a high myocardial specificity, whereas CK, AST, and LDH had a low myocardial specificity. In terms of duration, CK, CK-MB, and AST appeared in the early stage of myocardial injury and brevity, but troponin and LDH endured to later stages. 22 Among these indicators, we found that CK, CK-MB, troponin I, AST, and LDH increased concomitantly in the critical group. This shows that the myocardium may have sustained damage. Although a recent autopsy performed by Xu et al 17 showed that the cardiomyocytes of patients with COVID-19 were structurally intact, and they found only a small amount of inflammatory infiltration of mononuclear cells in the intercellular stroma. However, some case reports showed acute myocardial injury and cardiac dilatation in patients with confirmed COVID-19. When following a therapeutic approach including intravenous immunoglobulin and steroids, ejection fraction, ventricular size, and cardiac biomarkers normalized within 2 to 3 weeks. 23, 24 Thus, myocardial damage caused by SARS-CoV-2 infection varies greatly. Myocardial injury is significantly associated with fatal outcomes in COVID-19 cases, although the prognosis of patients with underlying CVD but without myocardial injury is relatively favorable. 21 Inflammation may be a potential underlying mechanism for myocardial injury. Other common mechanisms may include viral myocarditis, cytokine-driven myocardial damage, microangiopathy, and unmasked coronary artery disease. 25 In critical patients, C-reactive protein and procalcitonin, which are inflammatory indicators, deserve particular attention. Similar to patients with SARS-CoV and Middle East respiratory syndrome coronavirus infections, those infected with SARS-CoV-2 display an enhanced T-helper 1 cell response and the release of corresponding inflammatory factors. At the same time, the expression of interleukin-4 and interleukin-10 is increased, indicating an enhancement in the T-helper 2 cell response. 7,26 Inflammatory waterfalls highly proliferated proinflammatory CCR4 + CCR6 + T-helper 17 cells in CD4 + T cells, CD8 + T cells expressed high concentrations of cytotoxic particles, and excessive activation of T cells caused a stronger inflammatory storm. 17 Procalcitonin is a specific inflammatory indicator of bacterial infection, 27, 28 and its significant increase in critical patients with COVID-19 and CVD indicates that they are more susceptible to secondary bacterial infections. In our study, the overall mortality rate was consistent with that reported in previous studies. 7, 8, 14 Respiratory failure type I was the leading cause of death in patients with COVID-19, but some patients with both COVID-19 and CVD were prone to acute cardiovascular events. Circulating cytokines released during a severe systemic inflammatory response could lead to atherosclerotic plaque instability and rupture. We found that AMI was secondary to respiratory failure, and an inflammatory storm was the most common cause of death in patients with COVID-19 and CHD. Although evidence of substantial myocardial damage was inconclusive, 17 the accumulation of lactic acid and hypoxia caused by respiratory failure led to an abnormal vasoconstriction of the coronary arteries, and the occurrence of AMI was accelerated by myocardial hypoperfusion and hypercoagulability in the later stages of shock. According to the new international definition of AMI, 29 we considered that some patients with AMI should be categorized as having type 2 myocardial infarction. Because of the general lack of negative pressure cardiac catheterization, most patients did not receive optimal ischemia-reperfusion therapy (insitu thrombolysis was preferred), and the mortality rate was extremely high. Finally, we used a logistic regression model to explore the potential factors associated with patient death. The results showed that, among patients with COVID-19 with CVD, overweight/obesity combined with CHD, severe hypoxia, and lactic acid accumulation resulting from respiratory failure, may increase the risk of death. However, because of the limited sample size, future studies are needed to confirm these findings. Our study had some limitations. First, it was a descriptive study. With a limited number of cases, it was difficult to assess host risk factors for disease severity and mortality with multivariable-adjusted methods. Second, data from other centers indicate that individuals with diabetes mellitus accounted for a high proportion of critical patients. 7, 8 However, in the present study, although the percentage of patients with diabetes mellitus was higher in the critical group than in the noncritical group, diabetes mellitus was not related to the clinical outcome. This may be attributable to the small sample size of this study. Third, this study focused only on the onset and outcome of the disease. It lacked dynamic observations of disease progression and complete epidemiological investigation. Finally, considering the relatively small sample size, some statistically significant results might be possible, and the results should be interpreted carefully. SARS-CoV-2 is a completely novel virus, and our understanding of the pathogenic mechanism is poor. Patients with COVID-19 with CVD comprise a special group because of their severe grade and poor prognosis. Critical patients have a high inflammatory response and hypercoagulability. The neutrophil/lymphocyte ratio may be a predictor of disease severity. Overweight/obesity combined with CHD, severe hypoxia, and lactic acid accumulation resulting from respiratory failure were related to poor outcomes. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Clinical course and outcomes of critically ill patients with SARS-COV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Active monitoring of persons exposed to patients with confirmed covid-19 -United States Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding A novel coronavirus from patients with pneumonia in China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Clinical features of patients infected with 2019 novel coronavirus in Wuhan A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-NCOV) infected pneumonia (standard version) Hypertension Committee of the Chinese Medical Doctor Association, Hypertension Branch of the China Association for the Promotion of International Exchanges of Health Care Hypertension Branch of the Chinese Geriatrics Society ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC Prevalence of obesity and associated risk factors and cardiometabolic comorbidities in rural northeast China A prospective natural-history study of coronary atherosclerosis Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study The ignored parameter in the diagnosis of obstructive sleep apnea syndrome: the oxygen desaturation index Inflammatory markers in palatine tonsils of children with obstructive sleep apnea syndrome Pathological findings of COVID-19 associated with acute respiratory distress syndrome Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Effects of occupational stress on the activation of hemostatic and inflammatory system Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) The specificity of biochemical markers of cardiac damage: a problem solved Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin First case of COVID-19 complicated with fulminant myocarditis: a case report and insights Elevated troponin in patients with coronavirus disease 2019 (COVID-19): possible mechanisms The COVID-19 epidemic Acute phase reactant serum amyloid a in inflammation and other diseases PCT), contemporary indicator of infection and inflammation Incidence, trends, and outcomes of type 2 myocardial infarction in a community cohort None. None.